Longitudinal Assessment of Adults With Severe Asthma

NCT01976767 | Completed

• 1 other identifier: 10/H0721/66
• Study Type: observational
• Target: 725
• Locations: 0 countries
• Sites: N/A

Brief Summary

Cross-sectional study to characterize cohorts of subjects with asthma and healthy controls in terms of clinical features, physiological measurements and non-invasive measurement of biomarkers and develop phenotype handprints for adults with severe asthma

Conditions

Asthma

Keywords

Sputum; Clinical cohorts; Smokers; Asthma; Biopsies; Severe asthma; Collaborative research; Phenotyping; Lipidomics; Transcriptomics; Proteomics; Paediatric cohort; Systems Biology

Outcome Measures

Primary Outcomes (14)

• Asthma exacerbations

  Number, duration and severity of exacerbations over the time of the study

  3 years

• Lung function decline over the course of the study

  3 years

• Changes in asthma medication

  in particular ICS dose, over the duration of the study

  3 years

• Daily symptoms and short acting beta agonist (SABA) usage

  measured during the telemonitoring study

  3 years

• Asthma control questionnaire (ACQ) at baseline and changes over the course of the study

  3 years

• Upper airway symptoms as assessed by the sino-nasal outcomes test (SNOT) at baseline and changes over the course of the study

  3 years

• Sleep and daytime drowsiness as assessed by the Epworth sleepiness scale at baseline and changes over the course of the study

  3 years

• Measurement of pulmonary function including spirometry, plethysmography, bronchodilator reversibility and respiratory impedance by forced oscillation technique

  3 years

• Radiological parameters such as computerized tomography (CT) scan, including assessment of lung structure

  3 years

• Measurement of inflammatory cell counts in blood, sputum and bronchoalveolar lavage (BAL)

  3 years

• Histopathology of bronchial biopsies in a sub group of subjects

  immunohistochemistry for inflammatory cells and matrix remodelling

  3 years

• Transcriptomics, proteomics and metabolomics will be used on samples such as blood, urine and endobronchial biopsies

  to develop clinically useful phenotype handprints

  3 years

• Quality of life as assessed by the asthma quality of life questionnaire (AQLQ)

  3 years

• Anxiety and depression as assessed by the hospital anxiety and depression scale (HADS)

  3 years

Study Arms (4)

Cohort A

Adults: severe asthmatics on high dose ICS and / or OCS

Cohort B

Adults: current smokers or ex-smokers, severe asthmatics on high dose ICS and / or OCS

Cohort C

Adults: non-smokers, mild to moderate asthmatics on regular inhaled corticosteroids (ICS)

Cohort D

Adults: healthy volunteers, non-smokers, non-asthmatic with pre bronchodilator FEV1 \> 80% predicted

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

* Severe asthma cohorts: uncontrolled asthma symptoms or frequent severe exacerbations * Mild-moderate asthma cohorts: controlled or partially controlled asthma symptoms * Healthy controls: non-asthmatic healthy individuals free of significant disease

You may qualify if:

• Able to give written informed consent prior to participation in the study, which includes ability to comply with the requirements and restrictions listed in the consent form. Informed consent must be obtained prior to undertaking any study procedures.
• Male or female subject aged 18 years or older at screening.
• Able to complete the study and all measurements.
• Able to read, comprehend, and write at a sufficient level to complete study related materials.
• Subjects will be allowed to enrol in other studies while taking part on this study. However, Permission from the Scientific Board must be obtained to enrol or allow the continued participation of a subject enrolled in another study.

You may not qualify if:

• As a result of medical interview, physical examination or screening investigation the physician responsible considers the subject unfit for the study either because of the risk to the subject due to the study or the influence this may have on the study results.
• The subject has a history of recreational drug use or other allergy, which, in the opinion of the responsible physician, contra-indicates their participation.
• Subject is female who is pregnant or lactating or up to 6 weeks post partum or 6 weeks cessation of breast feeding. If a woman is subsequently found to have been pregnant at the time of an assessment data from that assessment will not be included in the analyses.
• The subject has participated within 3 months of the first dose in a study using a new molecular entity, or the first dose in any other study investigating drugs or having participated within three months in a study with invasive procedures. Any U-BIOPRED assessments should be deferred until 3 months after the first dose or invasive procedure. Permission from the Scientific Board must be obtained to enroll or allow the continued participation of a subject enrolled in another study.
• Those who, in the opinion of the investigator, have a risk of non-compliance with study procedures.
• The subject has a recent history of incapacitating psychiatric disorders
• History or current evidence of an upper or lower respiratory infection or symptoms (including common cold) within 2 weeks of baseline assessments (assessments should be deferred).

Sponsors & Collaborators

• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA): lead

Related Publications (3)

• Reinke SN, Naz S, Chaleckis R, Gallart-Ayala H, Kolmert J, Kermani NZ, Tiotiu A, Broadhurst DI, Lundqvist A, Olsson H, Strom M, Wheelock AM, Gomez C, Ericsson M, Sousa AR, Riley JH, Bates S, Scholfield J, Loza M, Baribaud F, Bakke PS, Caruso M, Chanez P, Fowler SJ, Geiser T, Howarth P, Horvath I, Krug N, Montuschi P, Behndig A, Singer F, Musial J, Shaw DE, Dahlen B, Hu S, Lasky-Su J, Sterk PJ, Chung KF, Djukanovic R, Dahlen SE, Adcock IM, Wheelock CE; U-BIOPRED Study Group. Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study. Eur Respir J. 2022 Jun 30;59(6):2101733. doi: 10.1183/13993003.01733-2021. Print 2022 Jun.

  PMID: 34824054 DERIVED

• Kolmert J, Gomez C, Balgoma D, Sjodin M, Bood J, Konradsen JR, Ericsson M, Thorngren JO, James A, Mikus M, Sousa AR, Riley JH, Bates S, Bakke PS, Pandis I, Caruso M, Chanez P, Fowler SJ, Geiser T, Howarth P, Horvath I, Krug N, Montuschi P, Sanak M, Behndig A, Shaw DE, Knowles RG, Holweg CTJ, Wheelock AM, Dahlen B, Nordlund B, Alving K, Hedlin G, Chung KF, Adcock IM, Sterk PJ, Djukanovic R, Dahlen SE, Wheelock CE; U-BIOPRED Study Group, on behalf of the U-BIOPRED Study Group. Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. Am J Respir Crit Care Med. 2021 Jan 1;203(1):37-53. doi: 10.1164/rccm.201909-1869OC.

  PMID: 32667261 DERIVED

• Emma R, Bansal AT, Kolmert J, Wheelock CE, Dahlen SE, Loza MJ, De Meulder B, Lefaudeux D, Auffray C, Dahlen B, Bakke PS, Chanez P, Fowler SJ, Horvath I, Montuschi P, Krug N, Sanak M, Sandstrom T, Shaw DE, Fleming LJ, Djukanovic R, Howarth PH, Singer F, Sousa AR, Sterk PJ, Corfield J, Pandis I, Chung KF, Adcock IM, Lutter R, Fabbella L, Caruso M; U-BIOPRED Study Group. Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort. PLoS One. 2018 Sep 21;13(9):e0203874. doi: 10.1371/journal.pone.0203874. eCollection 2018.

  PMID: 30240401 DERIVED

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Peter Sterk, Dr.

  Academic Medical Centre University of Amsterdam, The Netherlands

  PRINCIPAL INVESTIGATOR

• Ratko Djukanovic, Dr.

  Southampton General Hospital, UK

  PRINCIPAL INVESTIGATOR

• Stephen Fowler, Dr.

  Respiratory Research Group, Education and Research Centre, Wythenshawe Hospital, UK

  PRINCIPAL INVESTIGATOR

• Kian Fan Chung, Dr.

  Imperial College London, UK

  PRINCIPAL INVESTIGATOR

• Barbro Dahlén, Dr.

  Karolinska Institutet

  PRINCIPAL INVESTIGATOR

• Andrew Szczeklik, Dr.

  Uniwersytet Jagielloński - Collegium Medicum, Kraków, Poland

  PRINCIPAL INVESTIGATOR

• Thomas Geiser, Dr.

  Inselspital and University of Bern, Switzerland

  PRINCIPAL INVESTIGATOR

• Ildiko Horvath, Dr.

  University School of Medicine, Budapest, Hundary

  PRINCIPAL INVESTIGATOR

• Pascal Chanez, Dr.

  Université de la Méditerranee, Marseille, France

  PRINCIPAL INVESTIGATOR

• Jens Hohlfeld, Dr.

  Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover

  PRINCIPAL INVESTIGATOR

• Thomas Sandström, Dr.

  Department of Public Health and Clinical Medicine, Division of Medicine, Umea, Sweden

  PRINCIPAL INVESTIGATOR

• Dominick Shaw, Dr.

  Nottingham City Hospita, Nottingham, UK

  PRINCIPAL INVESTIGATOR

• Per Sigvald Bakke, Dr.

  Haukeland University Hospital, Bergen, Norway

  PRINCIPAL INVESTIGATOR

• Riccardo Polosa, Dr.

  Policlinico Vittorio Emmanuele, Catania, Italy

  PRINCIPAL INVESTIGATOR

• Paolo Montuschi, Dr.

  Fondazione Policlinico Universitario Agostino Gemelli IRCCS

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. dr.

Study Record Dates

• First Submitted: October 22, 2013
• First Posted: November 6, 2013
• Study Start: April 1, 2011
• Primary Completion: October 1, 2013
• Study Completion: April 1, 2014
• Last Updated: January 14, 2015

Record last verified: 2015-01